Search

502 Result(s)
Sort by

Corporate Compliance Program

Corporate Compliance Program

Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.
Clinical Development and Operations

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
About our Innovation Prize

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Our Innovation Prize | Partnering

Our Innovation Prize | Partnering

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.